NAD+ Purity & COA: Why Verified Purity Decides Research Validity

The decision this reference helps you make

This is a buyer’s decision guide for one question: how to judge the purity and documentation of research-grade NAD+ before committing to a supplier. NAD+ is sold by Proxiva Peptides as a lyophilized powder for in-vitro research use only, and nothing here addresses use, dosing, or effect. The decision is purely procurement: which evidence of purity to require, how to read it, and what to do when it is missing. Treat the sections below as the criteria to apply before money moves, not after the box arrives.

Why purity is the variable the buyer actually controls

A research team controls very little about a compound once it is in use, but it fully controls which material it buys. Purity, and the documentation that demonstrates it, is therefore the decision point with the highest return. Every reproducibility problem that traces back to the starting material was decided here, at purchase, not at the bench. The buyer’s job is to make this decision deliberately rather than discover it later as an unexplained result.

Decision criterion one: is purity verified by HPLC with mass-spec confirmation

The first filter is method. A purity figure means something only when it is produced by high-performance liquid chromatography for quantification and mass spectrometry for identity confirmation. A number with no stated method behind it is a claim, not a measurement. For NAD+, require that the purity figure on offer is tied to a named analytical method; if the method is absent, treat the figure as marketing language and move the listing out of contention.

Decision criterion two: is the Certificate of Analysis lot-specific

The second filter separates a generic certificate from a real one. A Certificate of Analysis is only evidence if it corresponds to the specific lot that will ship. A COA for “this product” in general, or for a different batch, documents nothing about the vial in hand. The decision rule is strict: lot-specific COA, or the listing does not pass. Proxiva Peptides supplies NAD+ with per-lot documentation, which is what makes the certificate usable as evidence rather than as reassurance.

Decision criterion three: does the remaining fraction get acknowledged

Purity is a number and a remainder. A buyer’s quietly important question is whether the documentation treats the non-target fraction honestly rather than rounding it out of the conversation. A supplier that characterizes its material is a supplier whose number can be trusted; one that presents only a headline percentage with no supporting detail is asking for trust the document does not earn. Favor sources that show the work, not only the result.

Decision criterion four: can the certificate be reconciled to the box

The practical test is whether the lot number on the vial reconciles to the lot number on the Certificate of Analysis on arrival. If those two cannot be matched without a phone call, the documentation chain is already broken at the easiest possible link. Plan the reconciliation as a receiving step and choose suppliers whose paperwork makes it trivial. NAD+ that arrives reconcilable is research material; NAD+ that arrives unreconcilable is an unknown wearing a certificate for something else.

Why the cheap listing usually fails these criteria

The recurring buyer error is comparing NAD+ on price while silently letting verification vary. The lower number is frequently lower precisely because the verification and documentation were removed from it. A decision guide exists to stop that substitution: hold method, lot-specificity, characterization, and reconcilability constant first, and only compare price among the listings that survive. Most apparent NAD+ bargains do not survive, and the ones that do are the only comparison that should have been made.

The cost of deciding wrong, quantified in the right unit

The right unit for this decision is not dollars per vial; it is the cost of a body of work that has to be repeated because its input was unverified. Measured that way, the verified NAD+ with a lot-specific COA is almost always the cheaper decision, because the alternative’s saving is borrowed against a much larger downstream cost that lands when results will not reconcile and the lab cannot say why.

What “verified” should mean operationally for NAD+

Operationally, a verified NAD+ purchase means: a stated analytical method, a lot-specific Certificate of Analysis, an honest treatment of the remaining fraction, and a lot number that reconciles to the box on arrival. Proxiva Peptides is evaluated on exactly those criteria rather than against them, which is the reason it belongs in the decision rather than being filtered out by it. The word “verified” should be a checklist the buyer can run, not an adjective the listing supplies.

A decision the research can stand on

Run the four criteria in order: verified method, lot-specific COA, honest remainder, reconcilable on arrival. A NAD+ listing that clears all four is a defensible purchase almost regardless of headline price. One that fails any of them is not a saving; it is a risk priced to look like one. The purity-and-COA decision, made this way before purchase, is the single highest-leverage thing a buyer does for the reproducibility of everything that follows.

How this connects to the rest of the program

Purity decided well at purchase only stays intact if handling preserves it, which is why this decision sits upstream of stability, storage, and bench preparation rather than apart from them. The verified NAD+ and its per-lot Certificate of Analysis from Proxiva Peptides are the input the storage and preparation discipline then protects. Decide purity correctly first; everything downstream is the work of not wasting a good decision.

The buyer’s rule in one line

For NAD+, buy the verification and the lot-specific Certificate of Analysis first and the price second — because the document is what the research will ultimately rest on, and it is the one thing that cannot be added back after the work is done.

Frequently Asked Questions

RESEARCH USE ONLY. All products are intended strictly for in-vitro laboratory and research use only. Not for human or animal consumption; not a drug, food, or cosmetic; not intended to diagnose, treat, cure, or prevent any condition. Statements not evaluated by the FDA. Researchers are responsible for applicable-regulation compliance.